

DRAFT

Please add the following new claims:

- 36. (new) A pharmaceutical composition according to claim 11 wherein the pharmaceutical composition is suitable for administration to the lungs by inhalation.
- 37. (new) A pharmaceutical composition according to claim 35 wherein the pharmaceutical composition is suitable for administration to the lungs by inhalation.
- 38. (new) A pharmaceutical composition for treating a mammal suffering from chronic obstructive pulmonary disease comprising an amount of 13-*cis*-retinoic acid or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof, and a pharmaceutically acceptable carrier, said amount being sufficient to alleviate at least one symptom of chronic obstructive pulmonary disease.
- 39. (new) A pharmaceutical composition according to claim 38 wherein the pharmaceutical composition is suitable for administration to the lungs by inhalation.
- 40. (new) A pharmaceutical composition suitable for preventing chronic obstructive pulmonary in human comprising an amount of 13-*cis*-retinoic acid or a pharmaceutically acceptable salt, hydrate, solvate, or pro-drug thereof and a pharmaceutically acceptable carrier, said amount being sufficient to prevent chronic obstructive pulmonary disease, wherein said pharmaceutical composition is in a form suitable for administration to the lungs by inhalation.
- 41. (new) A pharmaceutical composition according to claim 40 wherein the pharmaceutical composition is suitable for administration to the lungs by inhalation.
- 42. (new) The pharmaceutical composition of Claim 41, wherein said form is suitable for administration through a metered dose inhaler.
- 43. (new) The pharmaceutical composition of Claim 41, wherein said form is suitable for administration through a dry powder inhaler.
- 44. (new) The pharmaceutical composition of Claim 41 wherein said form is suitable for administration through a liquid spray device.
- 45. (new) The pharmaceutical composition of Claims 44, wherein said liquid spray device is an aerosol device.
- 46. (new) The pharmaceutical composition of Claim 45, wherein said aerosol device is a nebulizer or electrohydrodynamic aerosol device.
- 47. (new) The pharmaceutical composition of Claim 41, wherein the chronic obstructive pulmonary disease is emphysema, or chronic bronchitis.--